Biomea Fusion (BMEA) Corporate presentation summary

Transformative approach to diabetes and obesity

• Advancing two clinical-stage programs: icovamenib (oral menin inhibitor) and BMF-650 (oral GLP-1 receptor agonist) targeting diabetes and obesity, respectively.

• Icovamenib aims to restore beta-cell mass, offering durable HbA1c reduction and increased C-peptide in type 2 diabetes patients failing standard care.

• BMF-650 is designed for improved oral bioavailability and tolerability, with preclinical data showing robust weight loss and favorable safety.

• Both programs address significant unmet needs, with icovamenib targeting over 10M US T2D patients and BMF-650 aiming at over 100M US obese patients.

• Company is funded through key clinical readouts into Q1 2027.

Clinical and preclinical results for icovamenib

• Phase II trials show persistent HbA1c reduction and increased C-peptide after 12-week dosing, with effects lasting up to 52 weeks.

• Preclinical studies demonstrate selective menin inhibition, increased beta-cell proliferation, and synergy with GLP-1 therapies.

• Durable clinical activity observed in both insulin-deficient and GLP-1 inadequate responder T2D populations.

• Favorable safety profile with no treatment-related serious adverse events and comparable adverse event rates to placebo.

• Key opinion leaders highlight disease-modifying potential and lasting benefits without chronic dosing.

Ongoing and upcoming clinical trials

• Two Phase II trials (COVALENT-211 and COVALENT-212) are enrolling, targeting insulin-deficient T2D and T2D not controlled on GLP-1 therapies, with 26-week data expected in 4Q 2026.

• Phase IIb program uses optimal dose and regimen identified from prior studies, with endpoints including HbA1c and fasting plasma glucose changes.

• Phase I study for BMF-650 in obese volunteers is ongoing, with 28-day weight reduction data anticipated in 2Q 2026.

• Pipeline includes additional studies in type 1 diabetes and obesity, with full worldwide rights retained.